Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking... | April 19, 2023